

Atomoxetine (Strattera)

Selected References:

- Bro SP, et al. 2015. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol; 7:139-47.
- Bröms G, et al. 2023. Atomoxetine in Early Pregnancy and the Prevalence of Major Congenital Malformations: A Multinational Study. J Clin Psychiatry 16, 84(1).
- Brown JT, et al. 2019. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. Clin Pharmacol Ther; 106(1):94-102.
- Cohen JM, et al. 2017. Placental complications associated with psychostimulant use in pregnancy. Obstet Gynecol; 130(6):1192-201.
- Kallen B, et al. 2013. The Use of Central Nervous System Active Drugs During Pregnancy. Pharmaceuticals; 6(10):1221-86.
- Naguy A, et al. 2020. Atomoxetine in-focus! Asian J Psychiatr; 49:101634.
- Perugi G, et al. 2015. The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder. Expert Opin Pharmacother.;16(14):2193-204.
- Strattera Product Label. 2022
<https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=132852a6-5bff-15dd-255c-98309dd83630&type=display> [accessed Mar 2025].

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2025.

Atomoxetine (Strattera)

Selected References:

- Bove R, et al. 2014. Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. *Obstet Gynecol.* 124:1157-68. PMID: 25415167
- Ciplea AI, et al. 2020. Safety of potential breast milk exposure to IFN-beta or glatiramer acetate: One-year infant outcomes. *Neurol Neuroimmunol Neuroinflamm.* 7(4) e757.
- Ciplea AI, et al. 2022. Eighteen-month safety analysis of offspring breastfed by mothers receiving glatiramer acetate therapy for relapsing multiple sclerosis – COBRA study. *Mult Scler.* 2022 Sep;28(10):1641-1650.
- Comi G. and Moiola L. 1997. Copolymer-1. *Baillieres Clin Neurol.* 6(3):495-509.
- Fragoso YD, et al. 2013. Long-term effects of exposure to disease-modifying drugs in the offspring of mothers with multiple sclerosis: a retrospective chart review. *CNS Drugs.* 27(11):955-61.
- Fragoso YD, et al. 2010. Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series. *CNS Drugs.* 24(11):969-76.
- Fragoso YD, et al. 2013. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. *Clin Neurol Neurosurg.* 115:154-9. PMID: 22633835
- Giannini M, et al. 2012. Pregnancy and fetal outcomes after glatiramer acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study. *BMC neurology* 12.1, 124.
- Hellwig K, Gold R. 2011. Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis. *J Neurol.* 258(3):502-3.
- Herbstritt S, et al. 2016. Glatiramer acetate during early pregnancy: a prospective cohort study. *Multiple Sclerosis Journal* 22.6: 810-816.
- Kaplan S, Dragut CF, Ghimpeteanu A. Pregnancy and fetal outcomes following paternal exposure to glatiramer acetate. *Curr Med Res Opin.* 2024 May;40(5):821-825.
- Kaplan, S., Zeygarnik, M. & Stern, T. 2022. Pregnancy, Fetal, and Infant Outcomes Following Maternal Exposure to Glatiramer Acetate During Pregnancy and Breastfeeding. *Drug Saf* 45, 345-357.
- Lopez-Leon S, et al. 2020. A systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project. *J Neurol.* 267(9):2721-2731.
- Lu E, et al. 2014. Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs. *CNS Drugs* 28(5): 475-82.
- Sandberg-Wollheim M, et al. 2018. Pregnancy outcomes from the branded glatiramer acetate pregnancy database. *Int J MS Care.* 20:9-14.
- Weber-Schoendorfer C, et al. 2009. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. *Multiple Sclerosis Journal* 15.9: 1037-1042.
- Varytè G, et al. 2021. Pregnancy and multiple sclerosis: an update. *Curr Opin Obstet Gynecol.* 33(5):378-383
- Ziemssen T, et al. 2001. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. *Drug Safety;* 24:979-90.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.mothertobaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2025.

Atomoxetine (Strattera)

Selected References:

- AbuRaya B, Sadarangani M. 2018. Meningococcal vaccination in pregnancy. *Hum Vaccin Immunother* 14(4):1188-1196.
- Becerra-Culqui, T. A., et al. 2020. Safety of MenACWY-CRM vaccine exposure during pregnancy. *Vaccine*, 38(12), 2683-2690.
- Becerra-Culqui TA, et al. 2020. Safety of quadrivalent meningococcal conjugate vaccine in infants and toddlers 2 to 23-months old. *Vaccine* 38(2), 228-234.
- Becerra-Culqui TA, et al. 2021. Real-world evidence of quadrivalent meningococcal conjugate vaccine safety in the United States: a systematic review. *Hum Vaccin Immunother*, 17(5):1432-1441.
- Clark, D. R., et al. 2020. Influenza or Meningococcal Immunization During Pregnancy and Mortality in Women and Infants: A Pooled Analysis of Randomized Controlled Trials. *The Pediatric Infectious Disease Journal*, 39(7), 641-644.
- Crum-Cianflone, N., & Sullivan, E. 2016. Meningococcal Vaccinations. *Infectious Diseases and Therapy*, 5(2), 89-112.
- Findlow H, et al. 2019. Kinetics of maternally-derived serogroup A, C, Y and W-specific meningococcal immunoglobulin G in Malian women and infants. *Vaccine*, 37(18), 2477-2481.
- GlaxoSmithKline Biologicals SA. 2020. Menveo product labeling. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2dc730d5-55fd-4e98-8c8a-daa7d8f872b0>. Accessed 16 May 2025.
- Letson GW, et al. 1998. Meningococcal vaccine in pregnancy: an assessment of infant risk. *Pediatr Infect Dis J* 17:261-263.
- Mbaeyi SA, et al. 2020. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. *MMWR Recommendations and Reports*, 69(9), 1-41.
- Myers TR, et al. 2020. Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra®) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2016. *Vaccine*, 38(40), 6291-6298.
- Nasser R, et al. 2020. Are all vaccines safe for the pregnant traveler? A systematic review and meta-analysis. *Journal of Travel Medicine*, 27(2).
- National Center for Immunization and Respiratory Diseases. 2011. General recommendations on immunization — recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 28;60(2):1-64. Erratum in: *MMWR Recomm Rep*; 60:993.
- Psarris A, et al. 2019. Immunizations during pregnancy: How, when and why. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, 240, 29-35.
- The Centers for Disease Control and Prevention (CDC). <https://www.cdc.gov/vaccines/vpd/mening/index.html>.

Accessed 16 May 2025.

- World Health Organization (WHO). 2015. Meningococcal A conjugate vaccine: updated guidance, February 2015. Weekly epidemiological record. No. 8, 90: 57-62.
- Zheteyeva Y, et al. 2013. Safety of meningococcal polysaccharide-protein conjugate vaccine in pregnancy: a review of the Vaccine Adverse Event Reporting System. Am J Obstet Gynecol.; 208(6):478.e1-6.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.mothertobaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2025.

Atomoxetine (Strattera)

Selected References:

- Asada H. 2022. Recent topics in the management of herpes zoster. J Dermatol. 50(3):305-310.
- Centers for Disease Control and Prevention. 2024. Shingles: Signs & Symptoms. Available at: https://www.cdc.gov/shingles/signs-symptoms/?CDC_AAref_Val=https://www.cdc.gov/shingles/about/symptoms.html
- Centers for Disease Control and Prevention. 2021. Shingles: Breastfeeding and Special Circumstances. Available at: <https://www.cdc.gov/breastfeeding/breastfeeding-special-circumstances/maternal-or-infant-illnesses/shingles.html>.
- Frederick IB, et al. 1986. Excretion of varicella-herpes zoster in breast milk. Am J Obstet Gynecol; 154:1116-7.
- Hayward K, et al. 2018. Management of herpes zoster (shingles) during pregnancy. J Obstet Gynaecol 38(7):887-894.
- Ion A, et al. 2025. Varicella Zoster Virus Infection and Pregnancy: An Optimal Management Approach. Pathogens. 14(2):151.

- Nanthakumar MP, et al. 2021. Varicella Zoster in pregnancy. Eur J Obstet Gynecol Reprod Biol. 258:283-287.
- Rosamilia LL. 2020. Herpes Zoster Presentation, Management, and Prevention: A Modern Case-Based Review. Am J Clin Dermatol. 21(1):97-107.
- Schafer R, et.al. Herpes Zoster in Pregnancy. 2019 J Midwifery Womens Health. Mar;64(2):230-235.
- Singal A, et al. 2024. Herpes zoster infection in pregnancy: features and consequences. Arch Dermatol Res. 316(4):107.
- Werner RN, et al. 2017. European consensus-based (S2k) Guideline on the Management of Herpes Zoster – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. J Eur Acad Dermatol Venereol. 31(1):20-29.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en [MotherToBaby.org](https://www.MotherToBaby.org) .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2025.

Atomoxetine (Strattera)

Selected References:

- Barcz E, et al. 2007. Influence of Echinacea purpurea intake during pregnancy on fetal growth and tissue angiogenic activity. Folia Histochemica et Cytobiologica 45:Supp. 1; 35-39.
- Chow G, et al. 2006. Dietary echinacea purpurea during murine pregnancy: Effect on maternal hemopoiesis and fetal growth. Biol Neonate; 89: 133-138.
- Gallo M, et al. 2000. Pregnancy outcome following gestational exposure to echinacea. Arch Intern Med. 160:3141-3143.
- Heitmann K, et al. 2016. Pregnancy outcome after prenatal exposure to echinacea: The Norwegian Mother and Child Cohort Study. Eur J Clin Pharmacol. 72(5): 623-630.
- Huntley AL, et al. 2005. The safety of herbal medicinal products derived from Echinacea species. Drug Saf 28(5):387-400.
- Lewicka A, et al. 2019. Supplementation of plants with immunomodulatory properties during pregnancy and

lactation—maternal and offspring health effects. *Nutrients* 11(8):1958.

- Linde K, et al. 2009. Echinacea for preventing and treating the common cold. *Cochrane Database of Systematic Reviews* 2(2):CD000530
- Matthias A, et al. 2008. Bioavailability of Echinacea alkamides in human breast milk. *Planta Med*; 74-SL59.
- Natural Standard (Ed). Herbs & Supplements – Echinacea (*E. angustifolia* DC, *E. pallida*, *E. purpurea*). *Nature Medicine Quality Standard*. [Retrieved on November 2014]. naturalstandard.com
- Ondrizek RR, et al. 1999. Inhibition of human sperm motility by specific herbs used in alternative medicine. *J Assist Reprod Genet.* 16(2):87-91.
- Perri D, et al. 2006. Safety and efficacy of echinacea (*Echinacea angustifolia*, *E. purpurea* and *E. pallida*) during pregnancy and lactation. *Can J Clin Pharmacol* 13(3):e261-7.
- Peprah P, et al 2019. 'We are nothing without herbs': a story of herbal remedies use during pregnancy in rural Ghana. *BMC* 19(1):65.
- Sarecka-Hujar B, Szulc-Musiół B. 2022 Herbal Medicines—Are They Effective and Safe during Pregnancy? *Pharmaceutics*; 14(1):171.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2025.